Patients will now be able to access Eliquis and Sotyktu for significantly cheaper than their current list prices.

Bristol Myers Squibb (BMY) stock is in focus as the firm expands its direct-to-consumer offering ahead of a Sept. 29 deadline ...

Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...

Bristol Myers Squibb has reached for its wallet to avoid being left behind in the race to develop a new class of bispecific antibodies for cancer that have been billed as the next big thing in ...

Through its “BMS Patient Connect” platform, the company is lowering out-of-pocket costs and providing nationwide shipping, ...